Skip to main content
Erschienen in: Supportive Care in Cancer 8/2015

01.08.2015 | Original Article

Opioids have no negative effect on the survival time of patients with advanced lung cancer in an acute care hospital

verfasst von: Seigo Minami, Kosuke Fujimoto, Yoshitaka Ogata, Suguru Yamamoto, Kiyoshi Komuta

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this study is to determine whether or not opioid administration influenced the survival time of patients with advanced lung cancer in an acute care hospital setting.

Methods

This was a single institutional and retrospective study. We reviewed patients with advanced lung cancer who had died from January 2008 to December 2013 at the Osaka Police Hospital. We compared survival times, calculated from the time of the last hospitalization or the last chemotherapy, between patients who had not used any opioids, those who had used a low dose of opioids (<60 mg/day), and those who had used a higher dose of opioids (≥60 mg/day).

Results

A total of 369 patients, of which 284 had received chemotherapy, were analyzed. Opioid users were generally younger than nonusers. There was no significant difference in survival time after the last hospitalization in terms of opioid dose at the last admission and mean daily opioid dose; there was also no significant difference in survival time after the last chemotherapy in terms of the mean daily opioid dose and the opioid dose at death. Univariate and multivariate Cox proportional hazard analysis regarding survival time after the last hospitalization or the last chemotherapy did not reveal any opioid-related variables as a significant predictive factor.

Conclusions

Opioids were found to have no negative influence on survival time even in an acute care hospital.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Morita T, Tsunoda J, Inoue S, Chihara S (2000) Concerns of Japanese hospice inpatients about morphine therapy as a factor in pain management: a pilot study. J Palliat Care 16(4):54–58PubMed Morita T, Tsunoda J, Inoue S, Chihara S (2000) Concerns of Japanese hospice inpatients about morphine therapy as a factor in pain management: a pilot study. J Palliat Care 16(4):54–58PubMed
2.
Zurück zum Zitat Reid CM, Gooberman-Hill R, Hanks GW (2008) Opioid analgesics for cancer pain: symptom control for the living or comfort for the dying? A qualitative study to investigate the factors influencing the decision to accept morphine for pain caused by cancer. Ann Oncol 19(1):44–48PubMedCrossRef Reid CM, Gooberman-Hill R, Hanks GW (2008) Opioid analgesics for cancer pain: symptom control for the living or comfort for the dying? A qualitative study to investigate the factors influencing the decision to accept morphine for pain caused by cancer. Ann Oncol 19(1):44–48PubMedCrossRef
3.
Zurück zum Zitat Morita T, Miyashita M, Shibagaki M, Hirai K, Ashiya T, Ishihara T, Matsubara T, Miyoshi I, Nakaho T, Nakashima N, Onishi H, Ozawa T, Suenaga K, Tajima T, Akechi T, Uchitomi Y (2006) Knowledge and beliefs about end-of-life care and the effects of specialized palliative care: a population-based survey in Japan. J Pain Symptom Manag 31(4):306–316CrossRef Morita T, Miyashita M, Shibagaki M, Hirai K, Ashiya T, Ishihara T, Matsubara T, Miyoshi I, Nakaho T, Nakashima N, Onishi H, Ozawa T, Suenaga K, Tajima T, Akechi T, Uchitomi Y (2006) Knowledge and beliefs about end-of-life care and the effects of specialized palliative care: a population-based survey in Japan. J Pain Symptom Manag 31(4):306–316CrossRef
4.
Zurück zum Zitat Azoulay D, Jacobs JM, Cialic R, Mor EE, Stessman J (2011) Opioids, survival, and advanced cancer in the hospice setting. J Am Med Dir Assoc 12(2):129–134PubMedCrossRef Azoulay D, Jacobs JM, Cialic R, Mor EE, Stessman J (2011) Opioids, survival, and advanced cancer in the hospice setting. J Am Med Dir Assoc 12(2):129–134PubMedCrossRef
5.
Zurück zum Zitat Bercovitch M, Adunsky A (2004) Patterns of high-dose morphine use in a home-care hospice service: should we be afraid of it? Cancer 101(6):1473–1477PubMedCrossRef Bercovitch M, Adunsky A (2004) Patterns of high-dose morphine use in a home-care hospice service: should we be afraid of it? Cancer 101(6):1473–1477PubMedCrossRef
6.
Zurück zum Zitat Bercovitch M, Adunsky A (2006) High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharmacother 20(4):33–39PubMedCrossRef Bercovitch M, Adunsky A (2006) High dose controlled-release oxycodone in hospice care. J Pain Palliat Care Pharmacother 20(4):33–39PubMedCrossRef
7.
Zurück zum Zitat Bercovitch M, Waller A, Adunsky A (1999) High dose morphine use in the hospice setting. A database survey of patient characteristics and effect on life expectancy. Cancer 86(5):871–877PubMedCrossRef Bercovitch M, Waller A, Adunsky A (1999) High dose morphine use in the hospice setting. A database survey of patient characteristics and effect on life expectancy. Cancer 86(5):871–877PubMedCrossRef
8.
Zurück zum Zitat Morita T, Tsunoda J, Inoue S, Chihara S (2001) Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manag 21(4):282–289CrossRef Morita T, Tsunoda J, Inoue S, Chihara S (2001) Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manag 21(4):282–289CrossRef
9.
Zurück zum Zitat Portenoy RK, Sibirceva U, Smout R, Horn S, Connor S, Blum RH, Spence C, Fine PG (2006) Opioid use and survival at the end of life: a survey of a hospice population. J Pain Symptom Manag 32(6):532–540CrossRef Portenoy RK, Sibirceva U, Smout R, Horn S, Connor S, Blum RH, Spence C, Fine PG (2006) Opioid use and survival at the end of life: a survey of a hospice population. J Pain Symptom Manag 32(6):532–540CrossRef
10.
Zurück zum Zitat Thorns A, Sykes N (2000) Opioid use in last week of life and implications for end-of-life decision-making. Lancet 356(9227):398–399PubMedCrossRef Thorns A, Sykes N (2000) Opioid use in last week of life and implications for end-of-life decision-making. Lancet 356(9227):398–399PubMedCrossRef
11.
Zurück zum Zitat Fohr SA (1998) The double effect of pain medication: separating myth from reality. J Palliat Med 1(4):315–328PubMedCrossRef Fohr SA (1998) The double effect of pain medication: separating myth from reality. J Palliat Med 1(4):315–328PubMedCrossRef
12.
Zurück zum Zitat Sykes N, Thorns A (2003) The use of opioids and sedatives at the end of life. Lancet Oncol 4(5):312–318PubMedCrossRef Sykes N, Thorns A (2003) The use of opioids and sedatives at the end of life. Lancet Oncol 4(5):312–318PubMedCrossRef
13.
Zurück zum Zitat Morita T, Akechi T, Ikenaga M, Kizawa Y, Kohara H, Mukaiyama T, Nakaho T, Nakashima N, Shima Y, Matsubara T, Uchitomi Y (2005) Late referrals to specialized palliative care service in Japan. J Clin Oncol 23(12):2637–2644PubMedCrossRef Morita T, Akechi T, Ikenaga M, Kizawa Y, Kohara H, Mukaiyama T, Nakaho T, Nakashima N, Shima Y, Matsubara T, Uchitomi Y (2005) Late referrals to specialized palliative care service in Japan. J Clin Oncol 23(12):2637–2644PubMedCrossRef
Metadaten
Titel
Opioids have no negative effect on the survival time of patients with advanced lung cancer in an acute care hospital
verfasst von
Seigo Minami
Kosuke Fujimoto
Yoshitaka Ogata
Suguru Yamamoto
Kiyoshi Komuta
Publikationsdatum
01.08.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2592-6

Weitere Artikel der Ausgabe 8/2015

Supportive Care in Cancer 8/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.